Venous Leg Ulcers (VLU)

Pathophysiology & Etiology

Venous leg ulcers (VLUs) account for 70-90% of lower extremity chronic wounds. The underlying etiology is chronic venous insufficiency (CVI), characterized by venous hypertension due to valvular reflux, deep vein thrombosis (DVT) sequelae, or calf muscle pump dysfunction. Sustained ambulatory venous pressures (>40 mmHg) lead to microvascular dilation, endothelial damage, and perivascular fibrin cuff formation.

This environment traps leukocytes, which degranulate and release inflammatory cytokines and matrix metalloproteinases (MMPs), resulting in a cycle of chronic inflammation, tissue hypoxia, and eventual dermal breakdown.

VLUs typically present in the gaiter area (medial or lateral malleolus) and are associated with lipodermatosclerosis, pitting edema, hemosiderin staining, and atrophie blanche. The wound bed is often shallow with irregular, sloping edges and exhibits heavy, exudative drainage. Without addressing the underlying venous hypertension, these wounds are highly prone to recurrence, with lifetime recurrence rates exceeding 50%.

CEAP Classification

The CEAP (Clinical, Etiologic, Anatomic, Pathophysiologic) classification system provides a standardized framework for documenting venous disease severity:

• C0: No visible or palpable signs of venous disease.
• C1: Telangiectasias or reticular veins.
• C2: Varicose veins.
• C3: Edema.
• C4: Changes in skin and subcutaneous tissue secondary to CVD (C4a: pigmentation/eczema, C4b: lipodermatosclerosis/atrophie blanche).
• C5: Healed venous ulcer.
• C6: Active venous ulcer.

Suffixes are added to denote symptoms (S), absence of symptoms (A), telangiectasia (T), superficial vein reflux (Pr), perforator vein reflux (Pp), or deep vein reflux/obstruction (Pd/Po).

Standard of Care Framework

The cornerstone of VLU management is sustained compression therapy combined with wound bed preparation.

1. Compression Therapy: Multi-layer compression bandaging (e.g., Profore, Coban 2) delivering 40 mmHg at the ankle is the gold standard for reducing edema and improving venous return. Graduated compression stockings (30-40 mmHg) are used for maintenance after healing. Unna boots (zinc paste bandages) provide mild compression and a moist wound environment but are less effective for severe edema.
2. Debridement: Sharp debridement of hyperkeratotic wound edges, slough, and fibrinous debris is essential to convert the chronic wound to an acute state. Debridement removes senescent cells and MMP-rich fluid, exposing healthy granulation tissue.
3. Moist Wound Care: Highly exudative VLUs require absorptive dressings (foams, alginates, hydrofibers) to manage drainage and prevent maceration of the peri-wound skin. Barrier creams or zinc oxide protect the surrounding skin.
4. Venous Ablation: Early endovenous ablation of superficial refluxing veins (e.g., EVLT, radiofrequency ablation, sclerotherapy) significantly accelerates healing and reduces recurrence. Referral to vascular surgery should occur early in the treatment pathway.
5. Patient Education & Lifestyle: Leg elevation, calf muscle exercises, and weight management are critical adjuncts to clinical therapy.

Approximately 30-40% of VLUs fail to achieve 50% area reduction within 4-6 weeks of optimal compression therapy. These refractory wounds benefit from advanced biologic therapies.

Effective compression therapy is the single most critical intervention for VLU healing. The goal is to overcome ambulatory venous hypertension by providing sustained external pressure (35-45 mmHg at the ankle). Multi-layer bandage systems (e.g., 4-layer bandages) are superior to single-layer wraps due to their ability to maintain pressure over time and handle high exudate.

Endovenous thermal ablation or sclerotherapy of superficial venous reflux is now recommended earlier in the treatment algorithm (EVRA trial data) to reduce recurrence rates and accelerate healing.

Wound cleansing with saline or potable tap water is sufficient; cytotoxic agents like hydrogen peroxide or iodine should be avoided as they damage granulation tissue. Assessment of the Ankle-Brachial Pressure Index (ABPI) is mandatory before applying high-compression therapy to rule out significant arterial disease.

Biologics Integration

Biologics are indicated for VLU patients who demonstrate < 50% area reduction after 4 weeks of standard compression and wound care. They act by resetting the inflammatory microenvironment, supplying extracellular matrix (ECM) scaffolding, and delivering regenerative cytokines that stimulate fibroblast proliferation and angiogenesis.

Rampart Dual Layer Matrix

Given the typically high exudate levels and large surface area of VLUs, Rampart Dual Layer Matrix is the primary biologic intervention. Its dual-layer architecture is uniquely suited for VLUs: the porous base layer integrates into the wound bed to promote granulation, while the denser outer layer manages exudate and protects against external contamination.

Rampart's resistance to shear forces makes it ideal for the lower extremity, where movement and dressing changes are frequent. It serves as a temporary dermal substitute, filling tissue deficits and stimulating neovascularization in the chronic, MMP-depleted wound bed.

AmnioAMP-MP

As the VLU begins to contract and exudate decreases, AmnioAMP-MP can be utilized to accelerate the final phase of epithelialization. It is particularly effective on the wound margins and in areas where Rampart has successfully bedded but epithelial migration is slow. AmnioAMP-MP's thin, flexible profile conforms well to irregular contours and can be secured under standard compression bandaging without adding excessive bulk.

Application Under Compression

• Debride wound to a clean, bleeding base. Irrigate with sterile saline.
• Apply biologic matrix (Rampart for granulation, AmnioAMP-MP for epithelialization).
• Cover with a non-adherent silicone or petroleum contact layer.
• Apply secondary absorbent dressing appropriate for exudate level.
• Apply multi-layer compression bandaging (target 40 mmHg at ankle).
• Leave initial biologic in place for 3-5 days; assess integration at first dressing change.
• Reapply biologics every 2-4 weeks until complete epithelialization.

Recurrence Prevention

Following epithelialization, the risk of VLU recurrence is approximately 25-30% within the first year if compression therapy is abandoned. Patients should transition to graduated compression stockings (Class II or III, 20-40 mmHg) immediately after healing. Lifelong adherence to compression is the strongest predictor of recurrence-free survival.

Adjunctive measures include calf muscle exercise programs to improve the calf muscle pump function, skin hydration to prevent fissuring, and management of underlying risk factors such as obesity and venous hypertension. Regular duplex ultrasound surveillance may be indicated to detect new or recurrent reflux early.

Key References

1. Gloviczki P, et al. "The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum." J Vasc Surg. 2011;53(5 Suppl):2S-48S.
2. O'Donnell TF, Passman MA, Marston WA, et al.

"Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum." J Vasc Surg. 2014;60(2 Suppl):3S-59S.
3. Keo HH, et al. "Venous ulcers: Pathophysiology and management." Semin Vasc Surg. 2018;31(2-4):58-65.
4. Falanga V, et al. "Dehydrated human amnion/chorion membrane allografts augment healing of chronic venous leg ulcers." Wounds. 2015;27(10):254-262.
5.

NextGen Biologics Clinical Evidence Packets (Available upon request).
6. Weller CD, Buchbinder R, Johnston RV. "Interventions for helping people adhere to compression treatments for venous leg ulceration." Cochrane Database Syst Rev. 2015;(3):CD009718.